Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman(The Netherlands Cancer Institute), Esmée P. Hoefsmit(The Netherlands Cancer Institute), Irene L. M. Reijers(The Netherlands Cancer Institute), Robyn P.M. Saw(The University of Sydney), Judith M. Versluis(The Netherlands Cancer Institute), Oscar Krijgsman(The Netherlands Cancer Institute), Petros Dimitriadis(The Netherlands Cancer Institute), Karolina Sikorska(The Netherlands Cancer Institute), Bart A. van de Wiel(The Netherlands Cancer Institute), Hanna Eriksson(Karolinska University Hospital), Maria Gonzalez(The University of Sydney), A. Torres Acosta(The Netherlands Cancer Institute), Lindsay G. Grijpink-Ongering(The Netherlands Cancer Institute), Kerwin F. Shannon(The University of Sydney), John B.A.G. Haanen(The Netherlands Cancer Institute), Jonathan R. Stretch(The University of Sydney), Sydney Ch’ng(The University of Sydney), Omgo E. Nieweg(The University of Sydney), Henk Mallo(The Netherlands Cancer Institute), S. Adriaansz(The Netherlands Cancer Institute), Ron Kerkhoven(The Netherlands Cancer Institute), Sten Cornelissen(The Netherlands Cancer Institute), Annegien Broeks(The Netherlands Cancer Institute), W. Martin C. Klop(The Netherlands Cancer Institute), Charlotte L. Zuur(The Netherlands Cancer Institute), Winan J. van Houdt(The Netherlands Cancer Institute), Daniel S. Peeper(The Netherlands Cancer Institute), A. J. Spillane(The University of Sydney), Alexander C. J. van Akkooi(The Netherlands Cancer Institute), Richard A. Scolyer(The University of Sydney), Ton N. Schumacher(The Netherlands Cancer Institute), Alexander M. Menzies(The University of Sydney), Georgina V. Long(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute)
Nature Medicine
February 1, 2021
Cited by 333Open Access
Full Text

Abstract


Related Papers